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Abstract 
Frequencies of vanB-type Enterococcus faecium increased in Europe during the last years. VanB 
enterococci show various levels of vancomycin MICs even below the susceptible breakpoint 
challenging a reliable diagnostics. The performance of 3 chromogenic vancomycin-resistant 
enterococci (VRE) screening agars, 2 Etest® vancomycin protocols, and different microdilution 
methods to detect 129 clinical vanB E. faecium strains was investigated. Altogether, 112 (87%) were 
correctly identified as VanB-type Enterococcus by microdilution MICs. An Etest® macromethod 
protocol was more sensitive than the standard protocol while keeping sufficient specificity in identifying 
15 vanA/vanB-negative strains. Three chromogenic VRE agars performed similarly with 121 (94%), 
123 (95%), and 124 (96%) vanB isolates that grew on Brilliance
TM





 VRE agar, respectively. Using identical media and conditions, we did not identify 
different growth behaviour on agar and in broth. A few vanB strains showed growth of microcolonies 
inside the Etest® vancomycin inhibition zones, suggesting a VanB heteroresistance phenotype. 
 
Introduction 
Enterococci are important nosocomial pathogens, and multi- and vancomycin-resistant isolates of E. 
faecalis and E. faecium are of special concern in the health care setting. Altogether, 8 genotypes of 
acquired vancomycin resistance are known in Enterococcus spp. worldwide, but only vanA and vanB 
are clinically relevant genotypes (Werner 2012). VanA-type resistance is induced by all glycopeptides 
and, consequently and by definition, confers resistance to vancomycin and teicoplanin. The VanB type 
is characterised by susceptibility to teicoplanin (no inducer) and to varying levels of vancomycin 
resistance expression. However, glycopeptide resistance expression in wild-type strains may vary and 
MIC values are ambiguous and do not allow a proper determination of the corresponding genotype 
based on phenotypic test results. For example, vanA genotype vancomycin-resistant enterococci 
(VRE) exhibiting a VanB (VanD) phenotype, i.e., showing susceptible or intermediate MICs for 
teicoplanin, are documented worldwide ( Gu et al., 2009, Henrique et al., 2008, Park et al., 
2008 and Song et al., 2006). In addition, diagnostics of vanB type strains is challenged by varying 
expression levels of vancomycin resistance resulting in a wide range of MICs to vancomycin from ≤ 1 
to > 256 mg/L including concentrations that are defined as susceptible (≤ 4 mg/L) ( Courvalin, 
2006 and Depardieu et al., 2007). Expression levels do not correlate with the presence of different 
vanB allele types vanB1 to vanB3. All 3 subtypes are detected by molecular tests and vanB2 is the 
most prevalent ( Courvalin, 2006 and Werner et al., 2008). Detection of vanB type resistance by 
molecular methods circumvents the complications mentioned above with respect to a phenotypical 
measurement of resistance gene expression but conflicts with prevalence of vanB among 
nonenterococcal, intestinal colonizers ( Ballard et al., 2005, Domingo et al., 2005 and Graham et al., 
2008). The vanB gene prevalence in nonenterococcal, intestinal colonizers did not show a 
geographical preference and appeared at similar rates in different parts of the world as deduced from 
a number of clinical studies using real-time polymerase chain reaction (PCR)–based screening assays 
(Bourdon et al., 2010, Stamper et al., 2007, Usacheva et al., 2010, Werner et al., 2011b and Young et 
al., 2007). 
The problem of varying resistance gene expressions in VanB strains has been a matter of concern for 
a long time with regard to the proper identification of relevant strains (Jett et al., 1996 and Tenover et 
al., 1995). The supposed low overall prevalence of VanB resistance among clinical enterococci 
worldwide led to a comparably low recognition of this diagnostic problem until now. If and to what 
extent low-level vanB-type vancomycin resistance expression is clinically relevant could only be 
estimated from the few studies available so far. The described low-level resistance phenotype is linked 
to a weak induction of the resistance gene expression via the 2-component regulatory system VanRB–
VanSB. Inappropriate treatment by glycopeptides led to a selection of constitutively vancomycin- and 
teicoplanin-resistant vanB strains in vitro (Depardieu et al., 2003), in an experimental rat endocarditis 
model (Lefort et al., 2004) and under glycopeptide therapy in patients ( Hayden et al., 1993, Kawalec 
et al., 2001 and San Millan et al., 2009), which, as a consequence, caused treatment failures. 
The dramatic increase in vanB type prevalence among VRE in a number of European countries ( 
Bourdon et al., 2011, Klare et al., 2010 and Soderblom et al., 2010) requires a reliable and quick 
diagnostics of this resistant genotype and a differentiation from susceptible variants and other van 
genotypes. We evaluated the performance of 3 chromogenic VRE agars (Brilliance
TM





 VRE) and different MIC determination procedures (microbroth 
dilution, standard, and macromethod Etest®) in detecting 129 clinical E. faecium isolates possessing 
vanB. 
 
Materials and methods 
Strain collection 
Our laboratory serves as a national focal laboratory for enterococci since the beginning of the 1990s. 
Diagnostic and university laboratories send strains to us for (vancomycin/teicoplanin) resistance 
confirmation and molecular typing. Our enterococcal strain collection currently contains > 10,000 
isolates, mainly from hospital surveillance and infections, but also from animals, food products, the 
environment, and stool colonisations in outpatients (Klare et al., 1995a, Klare et al., 1995b, Klare et 
al., 1999, Klare et al., 2005, Werner et al., 2007, Werner et al., 2010 and Werner et al., 2011a). Until 
now, we collected and identified 1060 vanB strains including 982 vanB-positive E. faecium and 74 
vanB-positive E. faecalis which were all from hospital patients. Of the former, 129 vanB-type E. 
faecium isolates were selected for this study. They originated from 41 different diagnostic laboratories 
in Germany (which serve several hospitals), were isolated between 2005 and 2011, and showed 
different strain characteristics and a vancomycin MIC range of ≤ 1 to > 256 mg/L (determined by an 
accredited “in-house” method using broth microdilution in cation-adjusted Mueller-Hinton; see below). 
E. faecium ATCC 19434 and 15 E. faecium vanA/vanB-negative strains were used as negative 
controls. 
 
Antibiotic susceptibility testing 
For all E. faecium isolates, antibiotic susceptibilities were determined as MICs using a broth 
microdilution method using cation-adjusted Mueller-Hinton broth according to an accredited in-house 
procedure following the German standards of antimicrobial susceptibility testing (DIN, 2004). 
Classification into susceptible/intermediate/resistant (S-I-R) differs between European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) and Clinical Laboratory Standard Institutes (CLSI) 
(CLSI, 2011); EUCAST defines MICs for vancomycin with S ≤ 4 mg/L and R > 4 mg/L (no intermediate 
range) and CLSI defines S ≤ 4 mg/L, I = 8–16 mg/L, and R ≥ 32 mg/L. We used the EUCAST clinical 
breakpoints when available; for other antibiotics, we applied breakpoints derived from CLSI, DIN, and 
based on other criteria, e.g., for high-level ciprofloxacin resistance defined as an MIC > 16 mg/L ( 
Leavis et al., 2006 and Werner et al., 2010). Strains were classified as resistant with MICs (in 
milligrams per liter) as follows: penicillin/ampicillin > 8, teicoplanin > 2, erythromycin > 4, linezolid > 4, 
tetracycline > 4, rifampicin > 0.5, chloramphenicol > 16, tigecycline > 0.5, daptomycin > 4, gentamicin 
(high-level) > 128, streptomycin (high-level) > 512, quinupristin/dalfopristin > 4. Vancomycin MICs 
were also assessed by another microdilution method using VITEK® 2 (bioMérieux, Nürtingen, 
Germany). Samples were handled in a Smart Carrier Station (bioMérieux) and treated as 
recommended by the manufacturer. The correct inoculum was set using DensiCHECK
TM
 Plus 
(bioMérieux). Results were assessed as MICs leaving a preadjustment (CLSI, EUCAST, etc.) aside. 
The Advanced Expert System (AES
TM
; bioMérieux) subsequently evaluated the results on the basis of 
default EUCAST and CLSI (“CLSI global”) standards. Etest® for vancomycin was performed according 
to the recommendation of the manufacturer (bioMérieux). In brief, 2 different protocols were followed: 
first, a standard method with cation-adjusted Mueller-Hinton agar and an inoculum equivalent to 
McFarland standard 0.5 and, second, the so-called macromethod using brain heart infusion agar and 
an inoculum equivalent to McFarland standard 2.0. The latter protocol is suggested by the Etest® 
manufacturer (bioMérieux) for a confirmation of a supposed vancomycin resistance phenotype. Values 
are read after incubation at 35 °C for 24 h and again after 48 h (Etest® application sheet for 
Enterococcus/VRE and vancomycin EAS009). E. faecium ATCC 19434 was used as a control strain. 
The performance of 3 chromogenic VRE screening agars was evaluated: Oxoid Brilliance
TM
 VRE Agar 
(Thermo Scientific Fisher, Wesel, Germany), chromID
TM
 VRE (bioMérieux), and CHROMagar
TM
 VRE 
(Mast Diagnostika, Reinfeld, Germany). Strains were streaked out on selective plates and incubated 
as recommended by the manufacturers. Growth as single colonies and with equivalent colours was 
rated as a positive result. 
 
DNA Isolation and PCR 
Genomic DNA was prepared using a DNA extraction kit (DNeasy Tissue Kit, Qiagen, Hilden, 
Germany) according to the manufacturer's instructions. An initial cell wall lysis step was added 
dissolving the cell pellet in TES buffer (10 mmol/L Tris, 0.5 mmol/L ethylenediaminetetraacetic acid, 
10% sucrose [pH 8.0]) plus 10 mg/mL lysozyme (Roche Applied Science, Mannheim, Germany) 
followed by incubation at 37 °C for 30 min. PCR was performed with a PCR master mix 
(Fermentas/Thermo Fisher Scientific, St. Leon-Rot, Germany) according to the manufacturer's 
instructions. Approximately 0.5 μL of isolated genomic DNA (ca. 10 ng) and primers (200 nmol/L each) 
was added. Amplification of fragments representing the esp, hylEfm, and vanA/vanB genes was 
performed in a multiplex PCR as described elsewhere (Werner et al., 2011a). 
 
Statistics 




Determination of antibiotic susceptibilities 
MICs for 15 antibiotics were determined by microbroth dilution in cation-adjusted MH broth as 
recommended. Distribution of MIC50, MIC90, and the overall number of resistant strains among 129 
vanB VRE isolates is presented in Table 1. In addition, we assessed the MICs for vancomycin and 
teicoplanin by an alternative microdilution method in cation-adjusted MH broth as well (VITEK® 2). All 
isolates were resistant to ampicillin/penicillin and ciprofloxacin (high-level), suggesting the prevalence 
of vanB resistance genes among hospital-associated clonal types. All 129 vanB strains revealed 
susceptible MICs for teicoplanin of ≤ 0.5 mg/L (VITEK® 2) and ≤ 1 mg/L (in-house method). 
Standard microdilution determined a wide spectrum of vancomycin MICs ranging from ≤ 1 to > 256 
mg/L (Fig. 1A). According to CLSI, only 49% of strains were classified as “resistant” to vancomycin (R 
≥ 32 mg/L), and based on EUCAST criteria 86% were classified as vancomycin resistant (R > 4 mg/L); 
the latter is equivalent to a classification by CLSI combining “intermediate” and “resistant”. 
Resistances to antibiotics of last resort remained rare. Altogether, 17 vanB strains (13%) revealed 
MICs for vancomycin of ≤ 4 mg/L equivalent to a susceptible range defined by EUCAST and CLSI. 
Forty-eight (37%) exhibited MICs of 8 or 16 mg/L, which are intermediate according to CLSI. 
According to EUCAST definitions, altogether, 111 vanB strains could be classified as “resistant vanB-
like” (86%; MICs > 4 mg/L). Analyses by VITEK® 2 revealed vancomycin MICs in the susceptible 
range for 16 strains (12 %) and additional 64 isolates (49%) showed an MIC of 8 mg/L (intermediate 
according to CLSI; Fig. 1B). However, VITEK 2 AES
TM
 evaluation was independent of the 
corresponding standard set, also classifying strains with a vancomycin MIC of 8 mg/L (intermediate 
according to CLSI) correctly as “resistant* (vanB-like)”. All 15 vanA/vanB-negative E. faecium and the 
ATCC control strain revealed MICs for vancomycin and teicoplanin of ≤ 1 mg/L (not shown). 
The standard Etest® protocol using an inoculum of McFarland standard 0.5 and MH agar detected 21 
(16%) after 24 h and 18 (14%) of vanB strains with MICs of ≤ 4 mg/L after 48 h of incubation, 
respectively (Fig. 1C). All 15 vanA/vanB-negative E. faecium and the ATCC E. faecium control strain 
revealed vancomycin Etest® MICs of ≤ 1.5 mg/L (24/48 h), and 13 of them had an identical MIC after 
24 and 48 h. In contrast, vanB strains generally showed an elevated 48-h MIC versus the 24-h MIC 
(Fig. 1C). Etest® inhibition zones for vanA/vanB-negative E. faecium and the ATCC E. faecium control 
strain showed a sharp edge of growth inhibition, whereas most vanB strains expressed a specific 
phenotype with a shady growth at lower vancomycin concentrations (Fig. 2B and C), most probably 
related to the resistance phenotype induced after vancomycin exposure. This zone of weaker growth 
could span the range from susceptible to resistant MICs (Fig. 2B). Altogether, 2 vanB E. faecium 
strains showed microcolonies inside the inhibition zone (“heteroresistance phenotype”), 1 had an MIC 
of 32 mg/L and the other isolate was initially rated as susceptible with an MIC of 3 mg/L (Fig. 2D). 
According to the Etest® application recommendations, these strains should be classified as resistant 
with MIC > 256 mg/L. Microcolonies taken from inside the inhibition zone, grown overnight on MH agar 
plates, and tested again for Etest® vancomycin MICs revealed similar phenotypes as assessed 
before. The modified Etest® macromethod using McFarland 2.0 and BHI agar revealed altogether 
higher MICs for the 129 vanB E. faecium isolates (Fig. 1D), confirming the higher sensitivity of this 
alternative protocol. Altogether, 13 (10%; 24-h incubation) and 7 (5%; 48-h incubation) of the vanB 
strains showed MICs of ≤ 4 mg/L, respectively. With this protocol, all 15 vanA/vanB-negative E. 
faecium and the ATCC E. faecium control strain revealed vancomycin Etest® MICs of 3 mg/L after 24 
h of incubation and in all but 1 cases an identical value after 48 h (1 isolate had an MIC of 4 mg/L). Six 
isolates showed microcolony growth inside the Etest inhibition zone, suggesting a heteroresistance 
phenotype; 5 of them already possessed MICs of > 4 mg/L which would have been classified as 
resistant anyway (not shown in detail). 
 
Growth on screening agars 
We assessed growth of the 129 vanB strains and the 15 vanA/vanB-negative strains on 3 
chromogenic VRE agars: Brilliance
TM
 VRE Agar, chromID
TM
 VRE, and CHROMagar
TM
 VRE. 
Performance was similar on all 3 media (Table 2). In general, ≥ 86% of all vanB E. faecium grew on 
the tested screening agars, 4–5% grew in small colonies only (also rated as positive), and 4–6% did 
not grow at all. Growth behaviour was not always congruent on all 3 media but isolates that did not 
grow mainly possessed susceptible MICs as determined by the in-house microdilution, VITEK® 2, and 
Etest® method. Of the 15 non-vanA/vanB E. faecium strains, 14 did not grow on all media and 1 strain 
grew on 2 agar plates (Brilliance
TM
 VRE Agar and chromID
TM
 VRE). The susceptible ATCC E. faecium 
control strain did not grow on all chromogenic media. 
 
4. Discussion 
The numbers of infections and colonizations with vanB type VRE increased in a number of European 
countries during recent years ( Bourdon et al., 2011, Klare et al., 2010 and Soderblom et al., 2010). 
The supposed growing incidence of vanB type enterococci may have different reasons and could only 
be partly explained by an increased incidence of vanB type resistant strains. It cannot be excluded 
that the increased reporting of vanB type resistant enterococci may, at least in part, be attributed to the 
improved diagnostic capabilities of genotypic assays in targeting the corresponding resistance genes 
and to the introduction of sensitive chromogenic agar media in diagnosing corresponding vanB type 
enterococci. In addition, it is not known so far whether the reservoir of vanB resistance genes in 
nonenterococcal species may feed the resistance gene pool of Enterococcus spp. (Ballard et al., 
2005). The problem of low-level vancomycin resistance expression in vanB type enterococci has been 
known for a long time but has not been extensively studied or addressed until now, most probably due 
to its supposed low prevalence and thus moderate clinical significance ( Adler et al., 2010, Raponi et 
al., 2010 and Rathe et al., 2010). The low predictive value for vanB VRE according to the results of 
VRE screening studies performed in countries of different continents was mainly addressed to the 
wide prevalence of vanB genes in nonenterococcal, intestinal colonizers ( Rathe et al., 2010, Stamper 
et al., 2007, Usacheva et al., 2010 and Young et al., 2007). It has to be considered that a substantial 
number of vanB enterococci may have been missed in previous studies comparing the performance of 
real-time PCR-based screening assays against phenotypic comparator assays with a supposed low 
sensitivity in diagnosing vanB VRE with low-level vancomycin resistance expression (Werner et al., 
2011b). 
The strains in our study may not represent a common and naïve vanB genotype E. faecium population 
and thus the investigated strain collection may be biased by the following reasons: all strains were 
from clinical samples and represented hospital-associated strains of E. faecium (MLST CC17) 
according to their ampicillin/penicillin and high-level ciprofloxacin resistance phenotypes. In addition, 
markers only prevalent among hospital strains such as esp and hylEfm were widely prevalent among 
the tested 129 isolates (86% and 64%, respectively; not shown in details). Additionally, strains from 
the present study were preselected in laboratories performing primary diagnostics and sent to us for 
confirmation and further analysis, a number of them was suspicious in respect of the unsecured or 
discrepant diagnostic result for VanB when comparing genotypic and phenotypic assay results. 
The growth disadvantage of enterococci with an inducible vanB type resistance in MH broth has been 
described (Jett et al., 1996), and, correspondingly, several protocols including the Etest® 
macromethod suggest using rich media (BHI) for VRE confirmation. Thus far, results of our study were 
in line with results of previous reports; using rich media (BHI instead of MH) and a higher inoculum 
(McFarland 2.0 instead of 0.5) was also superior here (more sensitive) in identifying vanB type E. 
faecium strains with a low-level vancomycin resistance expression (Fig. 1C and D). As a negative 
control, all 15 vanA/vanB-negative E. faecium and the ATCC E. faecium control strain revealed 
susceptible vancomycin Etest® MICs of ≤ 4 mg/L (24/48 h). However, the macromethod protocol 
revealed comparably high values of 3 (4) mg/L near the susceptible breakpoint of ≤ 4 mg/L. It has to 
be emphasized that, due to unknown reasons, MICs for E. faecalis isolates appear 1–2 twofold 
dilutions higher than those for E. faecium (not shown) and, consequently, these assumptions are only 
suitable for vanB type E. faecium. 
When comparing vancomycin Etest results on MH agar using the standard protocol to the MIC results 
of VITEK® 2 (Fig. 1B) and of the in-house DIN protocol (Fig. 1A), it became obvious that resistance 
expression is not different on agar and in broth (Table 2). The performance of chromogenic VRE agars 
was superior to the standard Etest protocol results (24 h) and the MIC assays in liquid broth, but 
similar to the results of the Etest® macromethod (Table 2). Nevertheless, these assays have different 
applications (screening versus MIC determination) and a head-to-head comparison is, maybe, less 
reasonable. 
We describe here for the first time a heteroresistance phenotype for vancomycin for a few VanB 
isolates. The heteroresistance phenotype has only been described for a clinical vanA VRE and for in 
vitro–generated descendents of vanA-positive E. faecium strain ATCC 51559 ( Alam et al., 
2001 and Khan et al., 2008). Also, teicoplanin heteroresistance in vanA VRE strains was described 
recently (Qu et al., 2009). Several genomic rearrangements and deletions within the vanA gene cluster 
elements and mutational changes within the 2-component regulator genes vanS and vanR were 
identified in glycopeptide-heteroresistant strains, but whether these changes were functionally linked 
to the described heteroresistance phenotype has not been experimentally proven so far. In our hands, 
the high-level resistant colonies grown inside the inhibition zone were not stable after passage and 
showed the same phenomenon again. 
In conclusion, altogether, 112 vanB-type isolates (87%) were correctly identified as VanB type VRE by 
both microbroth dilution methods and when using interpretation criteria set as recommended by the 
manufacturer. The Etest® macromethod protocol using a higher inoculum of McFarland standard 2.0 
and 24/48 h of incubation on BHI agar was superior to the standard protocol with McFarland standard 
0.5 and MH agar in identifying VanB E. faecium strains while keeping sufficient specificity in correctly 
diagnosing 15 vanA/vanB-negative test and reference strains. A few vanB isolates showed growth of 
microcolonies inside the vancomycin inhibition zone, suggesting a VanB heteroresistance phenotype 
only detectable by Etest® vancomycin. Three commercial chromogenic VRE agars performed similarly 
with 121 (94%), 123 (95%), and 124 (96%) vanB isolates that grew on Brilliance
TM
 VRE Agar, 
CHROMagar
TM
 VRE, and chromID
TM
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Tables and Figures 
Table 1. Antibiotic susceptibilities of 129 vanB type Enterococcus faecium. 
 
a R according to EUCAST (> 4 mg/L; identical to I+R according to CLSI). 
b R according to CLSI (≥ 32 mg/L). 
c Only 110 VRE isolates were tested. 
d Only 105 VRE isolates were tested. 
 
 
Table 2. Results of MIC determinations and growth on chromogenic selective VRE agars of 129 vanB 
type E. faecium. 
 
MBD = In-house microdilution method in MH broth; MH = cation-adjusted Mueller-Hinton; BHI = brain 
heart infusion; CFU = colony-forming unit. Strains were classified as VanB phenotype when they were 
resistant to vancomycin according to EUCAST (R > 4 mg/L; identical to I+R according to CLSI. All 129 
strains were susceptible to teicoplanin (MIC ≤ 1 mg/L). 
 
 
Figure 1. Distribution of MICs for vancomycin determined by different test methods at 35–37 °C. (A) 
Results of in-house DIN microdilution in cation-adjusted Mueller-Hinton broth; (B) results of VITEK® 2 
(cation-adjusted Mueller-Hinton broth; bioMérieux); (C) Coventional Etest® Vancomycin on cation-
adjusted Mueller-Hinton agar after 24 and 48 h of incubation; and (D) Etest® Vancomycin 




Figure 2. Etest® Vancomycin phenotypes of Entercoccus faecium isolates on Mueller-Hinton agar. (A) 
Sharp inhibition zone of vanA/vanB-negative, vancomycin-susceptible strains; (B/C) atypical inhibition 
zone with shady growth showing resistant (B) and susceptible MICs (C), both vanB-type E. faecium; 
(D) growth of microcolonies inside the inhibition zone in some vanB-type E. faecium (heteroresistance 
phenotype). 
 
 
